Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > News > Canaccord Adams Initiates Coverage on AMAG Pharmaceuticals (AMAG) with a Buy

October 16th, 2008

Canaccord Adams Initiates Coverage on AMAG Pharmaceuticals (AMAG) with a Buy

Abstract:
Canaccord Adams initiates coverage on AMAG Pharmaceuticals (Nasdaq: AMAG) with a Buy rating and $57 target.

Canaccord analyst says, "Binary event but we believe data should enable first cycle approval...We acknowledge that there is controversy about whether AMAG has generated enough data for ferumoxytol approval. We believe that the Phase 3 studies demonstrated the strong efficacy and (more importantly) clean safety profile of ferumoxytol in CKD patients. We think that data also suggests that ferumoxytol may have the best safety profile, and importantly the lowest rates of anaphylaxis, of all the IV iron therapies. However, given the conservative FDA environment, we recognize that AMAG could receive a late approval or a request for more data...We believe that AMAG shares offer a compelling risk/benefit profile. AMAG shares are down almost 50% from their 52-week high in October 2007. We base our $57 price target on a pNPV analysis that assumes a 50% probability of a first-cycle approval for ferumoxytol. If ferumoxytol is approved, our pNPV analysis would yield a $95 value. If the FDA requests an additional study, our pNPV analysis would yield a $25 value."

Source:
streetinsider.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Physicists build reversible laser tractor beam October 20th, 2014

Removal of Limitations of Composites at Superheat Temperatures October 20th, 2014

1980s aircraft helps quantum technology take flight October 20th, 2014

Ucore's McKenzie to Deliver Presentation to Rare Earths Conference in Singapore as Highlight of Fall 2014 Marketplace Schedule October 19th, 2014

Investments/IPO's/Splits

Arrowhead Issues Open Letter to Shareholders October 9th, 2014

PEN Inc. Announces New Trading Symbol: PENC: Stock Continues Trading on the OTCQB September 3rd, 2014

Aspen Aerogels, Inc. to Present at Barclays CEO Energy-Power Conference August 27th, 2014

Harris & Harris Group Letter to Shareholders on Website August 19th, 2014

Nanomedicine

Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014

European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Tuning light to kill deep cancer tumors: Nanoparticles developed at UMass Medical School advance potential clinical application for photodynamic therapy October 15th, 2014

Announcements

Physicists build reversible laser tractor beam October 20th, 2014

Removal of Limitations of Composites at Superheat Temperatures October 20th, 2014

1980s aircraft helps quantum technology take flight October 20th, 2014

Ucore's McKenzie to Deliver Presentation to Rare Earths Conference in Singapore as Highlight of Fall 2014 Marketplace Schedule October 19th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE